| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Adenosine A3 receptor.
|
|---|---|
| ln Vitro |
VUF5574 is a potent, selective, and competitive antagonist of the human adenosine A3 receptor with a Ki of 4.03 nM. It displays ≥2500-fold selectivity over A1 and A2A receptors.
|
| ln Vivo |
No detailed in vivo activity data is available for this compound. As a selective A3 receptor antagonist, it is expected to have activity in inflammatory and immune-related conditions, but specific in vivo studies have not been reported.
|
| Enzyme Assay |
The compound's binding affinity to adenosine A3 receptor is assessed in cell-free radioligand binding assays using membrane preparations from cells expressing recombinant human A3 receptors. Competition binding experiments determine the Ki value of 4.03 nM.
|
| Cell Assay |
VUF5574 is evaluated in cell-based functional assays using cells expressing recombinant human A3 receptors. Second messenger assays or other signaling readouts measure the compound's ability to antagonize agonist-induced receptor activation, confirming its competitive nature.
|
| Animal Protocol |
No detailed in vivo animal experimental protocol is available for this compound. For A3 receptor antagonists, typical in vivo studies involve models of inflammation, asthma, or cancer to assess therapeutic potential.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data is available for VUF5574. With a molecular weight of approximately 450, specific PK parameters have not been reported.
|
| Toxicity/Toxicokinetics |
No detailed toxicological data is available for this compound. As a research-grade chemical probe, standard preclinical toxicity assessments have not been published.
|
| Additional Infomation |
VUF5574 is a potent, selective, and competitive antagonist of the human adenosine A3 receptor with high affinity and excellent selectivity over other adenosine receptor subtypes. It is a research tool for studying A3 receptor function in inflammation and immune responses. It has not advanced to clinical trials and is not FDA-approved.
|
| Molecular Formula |
C21H17N5O2
|
|---|---|
| Molecular Weight |
371.39198
|
| Exact Mass |
371.138
|
| CAS # |
280570-45-8
|
| PubChem CID |
4046493
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.36g/cm3
|
| Boiling Point |
444.8ºC at 760 mmHg
|
| Flash Point |
222.8ºC
|
| Vapour Pressure |
4.14E-08mmHg at 25°C
|
| Index of Refraction |
1.725
|
| LogP |
4.49
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
28
|
| Complexity |
519
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC=CC=C1NC(NC1=NC(C2C=CC=NC=2)=NC2=CC=CC=C12)=O
|
| InChi Key |
YRAFEJSZTVWUMD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H17N5O2/c1-28-18-11-5-4-10-17(18)24-21(27)26-20-15-8-2-3-9-16(15)23-19(25-20)14-7-6-12-22-13-14/h2-13H,1H3,(H2,23,24,25,26,27)
|
| Chemical Name |
1-(2-methoxyphenyl)-3-(2-pyridin-3-ylquinazolin-4-yl)urea
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~269.26 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.73 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6926 mL | 13.4629 mL | 26.9259 mL | |
| 5 mM | 0.5385 mL | 2.6926 mL | 5.3852 mL | |
| 10 mM | 0.2693 mL | 1.3463 mL | 2.6926 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
